Concepedia

Michael Skinner

MS

20

Publications

1.7K

Citations

18

H-Index

1981

Active since

Affiliations

Eli Lilly (United States)(Current)

Stanford University

The University of Texas Health Science Center at San Antonio

Indiana University – Purdue University Indianapolis

Westmead Hospital

Michael Skinner is an author at Eli Lilly (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top concepts

Publications per year

1981–2023

20

Publications

20

Digoxin sensitivity in amyloid cardiomyopathy.

Alan Rubinow, Michael Skinner, Alan S. Cohen · Circulation · 1981 · 241 citations · Full text

, , +17

Safety, Tolerability, and Changes in Amyloid β Concentrations After Administration of a γ-Secretase Inhibitor in Volunteers

Eric Siemers, Michael Skinner, Robert A. Dean et al. · Clinical Neuropharmacology · 2005 · 214 citations

METABOLISM, EXCRETION, AND PHARMACOKINETICS OF DULOXETINE IN HEALTHY HUMAN SUBJECTS

R. Clark Lantz, Todd A. Gillespie, T. J. Rash et al. · Drug Metabolism and Disposition · 2003 · 205 citations

Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers

Michael Skinner, Han‐Yi Kuan, Alan X. Pan et al. · Clinical Pharmacology & Therapeutics · 2003 · 189 citations

The Clinical Pharmacokinetics of Rifabutin

Terrence F. Blaschke, Michael Skinner · Clinical Infectious Diseases · 1996 · 138 citations

, , +14

Rows per page

1–5 of 20